Impact on Patients' Treatment Outcomes of XpertMTB/RIF Implementation for the Diagnosis of Tuberculosis: Follow-Up of a Stepped-Wedge Randomized Clinical Trial
Anete Trajman, Betina Durovni, Valeria Saraceni, Alexandre Menezes, Marcelo Cordeiro-Santos, Frank Cobelens, Susan Van den Hof, Anete Trajman, Betina Durovni, Valeria Saraceni, Alexandre Menezes, Marcelo Cordeiro-Santos, Frank Cobelens, Susan Van den Hof
Abstract
Introduction: The impact on treatment outcomes of XpertMTB/RIF, a molecular-based test that provides rapid diagnosis of tuberculosis (TB) and rifampicin resistance with high accuracy, has not been reported despite its adoption in a few countries. We here report treatment outcomes in a step-wedged cluster randomized trial for patients diagnosed with XpertMTB/RIF compared to patients diagnosed with sputum smear examination in public health facilities in Brazil.
Methods: Treatment outcome data were added to the trial database of patients diagnosed from 4 February to 4 October 2012, and crosschecked with data from the national mortality and the drug-resistant TB registers. Treatment outcomes in the intervention (n=2232) and baseline (n=1856) arms were compared using a multilevel regression model.
Results: Unfavourable outcomes were frequent in both arms, mainly due to loss to follow-up (16%). Overall unfavourable outcomes were not reduced in the intervention arm (29.6% versus 31.7%, OR=0.93; 95%CI=0.79-1.08). However, the overall TB-attributed death rate was lower in the intervention arm (2.3% vs. 3.8%). Adjusted for HIV status, age group and city, the intervention resulted in a 35% decrease in TB-attributed deaths (OR=0.65, 95%CI=0.44-0.97).
Conclusions: The proportion of patients successfully treated did not increase with Xpert MTB/RIF implementation, with high loss to follow-up rates in both arms. We did observe a 35% reduction in TB-related mortality, which we hypothesize may be explained by less advanced disease among the smear-negative patients diagnosed by Xpert. In conclusion, XpertMTB/RIF introduction did not improve TB treatment outcomes in Brazil.
Trial registration: clinicaltrials.gov NCT01363765.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363: 1005–1015. 10.1056/NEJMoa0907847
- Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, Pai M, et al. Xpert MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2013;1: CD009593 10.1002/14651858.CD009593.pub2
- Keeler E, Perkins MD, Small P, Hanson C, Reed S, Cunningham J, et al. Reducing the global burden of tuberculosis: the contribution of improved diagnostics. Nature. 2006;444: 49–57.
- World Health Organization. Road map for rolling out Xpert MTB/RIF for rapid diagnosis of TB and MDR-TB [Internet]. WHO.; 2010. Available:
- Durovni B. XpertMTB/Rif for diagnosing pulmonary tuberculosis: a stepped-wedge cluster-randomized trial. PLoS Med (in press). 2014;
- Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet. 2014;383: 424–435. 10.1016/S0140-6736(13)62073-5
- Nakiyingi L, Bwanika JM, Kirenga B, Nakanjako D, Katabira C, Lubega G, et al. Clinical predictors and accuracy of empiric tuberculosis treatment among sputum smear-negative HIV-infected adult TB suspects in Uganda. PLoS ONE. 2013;8: e74023 10.1371/journal.pone.0074023
- Churchyard G. Effect of Xpert MTB/RIF on early mortality in adults with suspected TB: a pragmatic randomized trial [Internet] CROI; 2014; Boston, USA: Available:
- Hayes RJ, Moulton LH. Cluster randomized trials. Boca Raton, Fla.; London: Chapman & Hall/CRC; 2009.
- Camargo KR Jr, Coeli CM. [Reclink: an application for database linkage implementing the probabilistic record linkage method]. Cad Saude Publica. 2000;16: 439–447.
- World Health Organization, Stop TB Initiative (World Health Organization). The treatment of tuberculosis guidelines [Internet]. Geneva: World Health Organization; 2010. Available:
- Theron G, Peter J, Dowdy D, Langley I, Squire SB, Dheda K. Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings? The Lancet Infectious Diseases. 2014; 10.1016/S1473-3099(13)70360-8
- Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJD. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS ONE. 2011;6: e17601 10.1371/journal.pone.0017601
- Lawn SD, Wood R, De Cock KM, Kranzer K, Lewis JJ, Churchyard GJ. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis. 2010;10: 489–498. 10.1016/S1473-3099(10)70078-5
- Osman M, Simpson JA, Caldwell J, Bosman M, Nicol MP. GeneXpert MTB/RIF Version G4 for Identification of Rifampin-Resistant Tuberculosis in a Programmatic Setting. J Clin Microbiol. 2014;52: 635–637. 10.1128/JCM.02517-13
Source: PubMed